Target
Glycogen synthase kinase-3 beta
Ligand
BDBM50150698
Substrate
n/a
Meas. Tech.
ChEMBL_312789 (CHEMBL833438)
IC50
2.6±n/a nM
Citation
 Engler, TAMalhotra, SBurkholder, TPHenry, JRMendel, DPorter, WJFurness, KDiefenbacher, CMarquart, AReel, JKLi, YClayton, JCunningham, BMcLean, JO'toole, JCBrozinick, JHawkins, EMisener, EBriere, DBrier, RAWagner, JRCampbell, RMAnderson, BDVaughn, RBennett, DBMeier, TICook, JA The development of potent and selective bisarylmaleimide GSK3 inhibitors. Bioorg Med Chem Lett 15:899-903 (2005) [PubMed]  Article 
Target
Name:
Glycogen synthase kinase-3 beta
Synonyms:
GSK-3 beta | GSK-3, beta | GSK3B | GSK3B_HUMAN | Glycogen synthase kinase 3 beta (GSK3B) | Glycogen synthase kinase 3-beta (GSK3B) | Glycogen synthase kinase-3 beta (GSK-3B) | Glycogen synthase kinase-3 beta (GSK3 Beta) | Glycogen synthase kinase-3 beta (GSK3B) | Glycogen synthase kinase-3B (GSK-3B) | Glycogen synthase kinase-3beta (GSK3B) | Serine/threonine-protein kinase GSK3B
Type:
Enzyme
Mol. Mass.:
46756.38
Organism:
Homo sapiens (Human)
Description:
P49841
Residue:
420
Sequence:
MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST
  
Inhibitor
Name:
BDBM50150698
Synonyms:
3-(imidazo[1,2-a]pyridin-3-yl)-4-(2-(morpholine-4-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-1H-pyrrole-2,5-dione | 3-Imidazo[1,2-a]pyridin-3-yl-4-[2-(morpholine-4-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl]-pyrrole-2,5-dione | CHEMBL178737
Type:
Small organic molecule
Emp. Form.:
C27H24N6O4
Mol. Mass.:
496.5173
SMILES:
O=C(N1CCOCC1)N1CCn2cc(C3=C(C(=O)NC3=O)c3cnc4ccccn34)c3cccc(C1)c23 |t:15|
Structure:
Search PDB for entries with ligand similarity: